Legend: Palais des congrès de Montréal = CC, Le Westin Montréal = W, Intercontinental Montréal = I
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 468 * | Wed, 8/7/2013, 8:30 AM - 10:20 AM | CC-510b | |
| Statistical Innovations Developed for Cancer Clinical Trials — Topic Contributed Papers | |||
| Biopharmaceutical Section , Biometrics Section | |||
| Organizer(s): Ying Wan, Janssen Research & Development | |||
| Chair(s): Sudhakar Rao, Janssen Research & Development | |||
| 8:35 AM | How to Maximize the Usefulness of Predictive Biomarker Data in Development of Personalized Medicines — Cong Chen, Merck and Company Inc | ||
| 8:55 AM | Meta-Analytic Evalution of Surrogate Endpoints in Clinical Studies — Geert Molenberghs, Universiteit Hasselt & Katholieke Universiteit Leuven | ||
| 9:15 AM | Joint Analysis of Progression and Survival with Missing Data from a Cancer Clinical Trial — Dianne Finkelstein, MGH and Harvard University ; David A Schoenfeld, MGH and Harvard University | ||
| 9:35 AM | Simulation-Guided Clinical Trial Design: Does It Improve the Final Design? — J. Kyle Wathen, Johnson & Johnson | ||
| 9:55 AM | Discussant: Lisa Meier McShane, NIH | ||
| 10:15 AM | Floor Discussion | ||
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.